30 mai-2 juin 2022
\nSingapour<\/p>\n
ENYO Pharma et ses collaborateurs ont pr\u00e9sent\u00e9 les derniers r\u00e9sultats sur l’effet de Vonafexor sur l\u2019h\u00e9patite B lors du congr\u00e8s \u00ab The Science of HBV Cure \u00bb.
\n“Effets antiviraux de l’agoniste du r\u00e9cepteur farn\u00e9so\u00efde X oral Vonafexor combin\u00e9 avec l’interf\u00e9ron p\u00e9gyl\u00e9 alpha2a chez les patients non trait\u00e9s atteints d’h\u00e9patite B chronique”.<\/p>\n
https:\/\/scienceofhbvcure.org\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" 30 mai-2 juin 2022 ENYO Pharma et ses collaborateurs ont pr\u00e9sent\u00e9 les derniers r\u00e9sultats sur l’effet de Vonafexor sur l\u2019h\u00e9patite B lors du congr\u00e8s \u00ab The Science of HBV Cure \u00bb. https:\/\/scienceofhbvcure.org\/<\/a><\/p>\n Lire la suite »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-4263","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"30 mai-2 juin 2022 Singapour ENYO Pharma et ses collaborateurs ont pr\u00e9sent\u00e9 les derniers r\u00e9sultats sur l’effet de Vonafexor sur l\u2019h\u00e9patite B lors du congr\u00e8s \u00ab The Science of HBV Cure \u00bb. “Effets antiviraux de l’agoniste du r\u00e9cepteur farn\u00e9so\u00efde X oral Vonafexor combin\u00e9 avec l’interf\u00e9ron p\u00e9gyl\u00e9 alpha2a chez les patients non trait\u00e9s atteints d’h\u00e9patite B…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4263"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4263\/revisions"}],"predecessor-version":[{"id":4265,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4263\/revisions\/4265"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nSingapour<\/p>\n
\n“Effets antiviraux de l’agoniste du r\u00e9cepteur farn\u00e9so\u00efde X oral Vonafexor combin\u00e9 avec l’interf\u00e9ron p\u00e9gyl\u00e9 alpha2a chez les patients non trait\u00e9s atteints d’h\u00e9patite B chronique”.<\/p>\n